

PARI and Kamada Expand Collaboration for Additional Inhaled AAT Indications

Monterey, California, February 26, 2008 – Following the successful results of Kamada's (TASE: KMDA) Phase I clinical trial for their inhaled Alpha-1 Antitrypsin (AAT) liquid drug candidate delivered by PARI's optimized eFlow® electronic nebulizer, both companies have expanded their collaboration agreement to additional indications for inhaled AAT. The joint clinical development and marketing of aerosolized AAT by Kamada and PARI Pharma will add the following indications: Alpha-1 Antitrypsin Deficiency, cystic fibrosis, and bronchiectasis.

"We are seeing good initial clinical success with inhaled AAT, so it only makes sense to look into additional possibilities for patients," said Dr. Martin Knoch, President of PARI Pharma GmbH. "We are pleased to continue seeing the technical advancements in eFlow garner good results in clinical trials with our pharmaceutical development partners."

Kamada will soon start a Phase II clinical trial to test inhaled Alpha-1 Antitrypsin (AAT) as a treatment for bronchiectasis, a lung disease that results in the distortion of one or more of the conducting bronchi or airways, most often secondary to an infection.

Inhaled AAT was designated, both in Europe and in the USA, as an orphan drug for the treatment of congenital emphysema and cystic fibrosis. The European Medicines Agency (EMA) has already approved Phases II-III of Kamada's clinical plan for treating Alpha-1 Antitrypsin deficiency with the company's aerosolized AAT product.

About eFlow

eFlow, an electronic, portable nebulizer, enables extremely efficient aerosolization of liquid medications via a vibrating, perforated membrane. Compared to other nebulizer systems, eFlow can produce aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible period of time. Combined with its silent mode of operation, small size (it fits in the palm of your hand), light weight, and battery use, eFlow helps reduce the burden of taking daily, inhaled treatments.

For additional information please see www.paripharma.com.

About Kamada

Kamada is a publicly traded biopharmaceutical company (TASE: KMDA) developing, producing, and marketing a line of specialty biotherapeutics using its proprietary chromatographic purification technologies. Licensed and marketed in more than 15 countries, several of these biotherapeutics hold registered and pending patents and are currently in advanced clinical trials. Additional information is available at www.kamada.com.

About PARI Pharma

PARI Pharma develops aerosol delivery devices and inhaled therapies. Based on PARI's 100-year history working with aerosols, PARI Pharma specializes in treatments for pulmonary and nasal administration optimized to advanced delivery platforms, such as eFlow.

Focusing on comprehensive inhalation therapy development, including optimized nebulizer formulations, analytics, and aerosol characterization, PARI Pharma has several clinical development programs ongoing, either partnered or proprietary. PARI Pharma, a PARI Medical Holding company, is located in Munich, Germany, with a major presence in the United States. Online at www.paripharma.com.

Additional information is available by contacting Kirsten Ayars at 805-452-7909 or Geoff Hunziker at 831-372-3580.

###

Kirsten Ayars
Ayars & Associates
strategic public affairs consulting
kayars@cox.net
805.845.5682 (office) 805.452.7909 (cell)